What published sources report about combining MDMA with an SSRI: blunted effects in a citalopram study, serotonin syndrome reports, and why a prescriber decides.
Taking MDMA (3,4-methylenedioxymethamphetamine) with an SSRI (selective serotonin reuptake inhibitor) antidepressant carries two separate problems in the published sources. We read the studies, case reports and MedlinePlus page cited here on October 13, 2026. A controlled study found that the SSRI citalopram markedly reduced most of MDMA's subjective effects, and case reviews and case reports describe serotonin syndrome and fatal serotonin toxicity when MDMA is combined with serotonergic antidepressants.
None of these sources says whether the combination is safe for a specific person. If you take an antidepressant, any change to it is the prescriber's decision. Do not stop or adjust it on your own.
Combining MDMA with an SSRI raises two separate problems in the published record: an SSRI given beforehand reduced MDMA's effects in a controlled study, and the combination is linked to serotonin syndrome.
The first problem comes from a controlled study in healthy volunteers. According to Liechti and Vollenweider, pretreatment with the SSRI citalopram "markedly reduced most of the subjective effects of MDMA."
The second problem is toxicity. A 2013 literature review states that MDMA combined with SSRIs "can lead to rapid, synergistic rise of serotonin (5-HT) concentration in the central nervous system, leading to the acute medical emergency known as serotonin syndrome."
The citalopram study measured subjective, cardiovascular and adverse effects in volunteers. Serotonin syndrome risk is a separate question, and the 2013 review describes the clinical and basic lab data on it as "scarce."
If you take an antidepressant, these sources do not say whether the combination is safe or unsafe for you. That question belongs with your prescriber. For other drug combinations, read our psychedelic medication safety guide.
In a 2001 summary of mechanistic studies, citalopram given before MDMA reduced most of MDMA's subjective effects in 16 healthy volunteers.
The summary covered 44 healthy volunteers who received one of three pretreatments before oral MDMA. Sixteen received the SSRI citalopram intravenously, 14 received the 5-HT2 antagonist ketanserin, and 14 received the D2 antagonist haloperidol. Each arm used a double-blind, placebo-controlled, within-subject design.
The authors report: "Citalopram markedly reduced most of the subjective effects of MDMA, including positive mood, increased extraversion and self-confidence. Cardiovascular and adverse effects of MDMA were also attenuated by citalopram."
The authors conclude that MDMA's overall psychological effects "largely depend on carrier-mediated 5-HT release."
A 2000 paper by the same authors reported a double-blind, placebo-controlled study in 16 healthy volunteers. Citalopram pretreatment reduced the MDMA-induced rises in blood pressure and heart rate and other physiological changes. Body temperature was the exception, and increased body temperature is also on the MedlinePlus list of serotonin syndrome symptoms.
These were healthy volunteers given a single intravenous dose of citalopram. People who take an SSRI every day over a long period were not studied, so what happens in that group is not on our record.
Serotonin syndrome is "a potentially life-threatening reaction to certain medicines," according to MedlinePlus. It most often occurs when two or more medicines or drugs that affect the body's serotonin level are taken together.
MedlinePlus lists street drugs including ecstasy among the drugs that can be involved. It also lists triptans taken with SSRIs or SSNRIs, and monoamine oxidase inhibitors (MAOIs) taken with the same medicines.
According to MedlinePlus, symptoms occur within minutes to hours of taking medicines that can cause serotonin syndrome. Symptoms can include agitation or restlessness, abnormal eye movements, diarrhea, fast heartbeat and high blood pressure, hallucinations and increased body temperature. Loss of coordination, nausea and vomiting, overactive reflexes, and rapid changes in blood pressure are also listed.
The 2013 review in the International Journal of Adolescent Medicine and Health focuses on adolescents and young adults who are prescribed SSRIs and use ecstasy recreationally. It warns of a rapid, synergistic rise in serotonin and states that clinical and basic lab data on this risk are scarce.
The fatal cases on our record involve a different antidepressant class. A 2012 report in Forensic Science International described four cases in Australia of fatal serotonin toxicity from MDMA combined with moclobemide, a reversible MAO-A inhibitor. Moclobemide is not an SSRI.
In some of those cases, paramedics and medical staff reported hyperthermia, hyperkalemia, profuse sweating, twitching and shaking. Three of the four cases presented with some form of heart disease. No fatality report involving an SSRI and MDMA is on our record.
MedlinePlus says to contact your provider right away if you have symptoms of serotonin syndrome, and that its information should not be used during a medical emergency. In an emergency, call your local emergency number or use our crisis resources page.
Psilocybin trials usually require participants to stop SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) before enrolling, according to a 2024 paper, while the antidepressant rules of MDMA trials are not on our record.
The 2024 paper in the Journal of Psychopharmacology states that "due to the lack of safety data on combining psilocybin with" SSRIs and SNRIs "and concerns that there may be a negative interaction on efficacy, participants enrolling in psychedelic trials are usually required to discontinue" them. That statement concerns psilocybin trials.
In an exploratory post hoc analysis of one trial, participants in the psilocybin group who had stopped SSRIs or SNRIs had a reduced treatment effect on all outcome measures, compared with patients who were unmedicated at entry. The authors say they cannot infer causation.
The same authors call for a controlled trial of discontinuation versus continuation. Results from that trial would change what we can report about stopping an antidepressant before psilocybin therapy. Our guide to psilocybin and antidepressants covers psilocybin separately.
For MDMA, the 2023 phase 3 trial in Nature Medicine was a multi-site, randomized, double-blind study of MDMA-assisted therapy for moderate to severe post-traumatic stress disorder (PTSD). It enrolled 104 participants, with 53 receiving MDMA-assisted therapy and 51 receiving placebo with therapy.
The abstract of that trial does not state any rule about antidepressants or SSRIs, so its SSRI rules are not on our record. To look up a specific study, use our clinical trial finder.
The published findings on MDMA and SSRIs translate into a short set of questions for the person who prescribes your antidepressant. None of these questions is an instruction to take or stop anything.
Ask which class your antidepressant belongs to, because MedlinePlus lists SSRIs, SSNRIs and MAOIs separately among the medicines involved in serotonin syndrome. Ask whether any other medicine you take affects serotonin levels.
Ask which symptoms of serotonin syndrome apply to you, and who to call if they appear. MedlinePlus says symptoms can start within minutes to hours.
If you are considering a clinical trial, ask what changing your antidepressant would involve for you. Tapering has its own risks, and weighing them is a clinician's job. You can also ask what the 2024 psilocybin analysis, which found a reduced treatment effect in people who had stopped SSRIs or SNRIs, means for your situation.
Bring a written list of every medicine you take. See also our medication safety checker.
MDMA is a Schedule I controlled substance under federal law, listed as 3,4-methylenedioxymethamphetamine with code 7405 in 21 CFR 1308.11 (Title 21 of the Code of Federal Regulations).
According to our guide to whether MDMA is legal in the US, MDMA-assisted therapy is available only in authorized research. That guide covers federal status, clinical use and access. For state rules, use our legal status by state tool.
Our MDMA guide covers the substance itself, and our guide to mixing MDMA and psilocybin covers a different combination. For antidepressant options, read our guide to SSRI alternatives.
Before any decision about MDMA and SSRI medication, take the questions above and the MedlinePlus serotonin syndrome page to the prescriber who manages your antidepressant.
The sources on our record report two problems with the combination. In a controlled study, the SSRI citalopram markedly reduced most of MDMA's subjective effects, and a 2013 review warns that MDMA with SSRIs can lead to serotonin syndrome. Whether the combination is safe for a specific person is a question for that person's prescriber.
Liechti and Vollenweider concluded that MDMA's overall psychological effects largely depend on carrier-mediated serotonin (5-HT) release. When volunteers received citalopram before MDMA, most subjective effects, including positive mood, extraversion and self-confidence, were markedly reduced. That study used a single intravenous dose in healthy volunteers, so it does not describe people on long-term SSRI treatment.
MedlinePlus defines serotonin syndrome as a potentially life-threatening reaction to certain medicines. It most often occurs when two or more medicines or drugs that affect the body's serotonin level are taken together. MedlinePlus lists ecstasy among the street drugs that can be involved.
MedlinePlus says symptoms occur within minutes to hours and can include agitation or restlessness, fast heartbeat, high blood pressure, increased body temperature, overactive reflexes, nausea, vomiting and diarrhea. It says to contact your provider right away if you have symptoms. In an emergency, call your local emergency number.
The antidepressant rules of MDMA trials are not on our record. The abstract of the 2023 phase 3 trial of MDMA-assisted therapy for PTSD states no rule about SSRIs. A 2024 paper says participants in psychedelic trials are usually required to stop SSRIs and SNRIs, but that paper is about psilocybin trials.
Do not stop an antidepressant on your own. Any change is a decision to make with your prescriber, and tapering has its own risks that a clinician has to weigh. See also our medication safety checker at /tools/medication-safety-checker.
MDMA is a federal Schedule I controlled substance, listed under code 7405 in 21 CFR 1308.11. According to our guide on MDMA legal status, MDMA-assisted therapy is available only in authorized research.
Get MDMA and SSRIs research & policy updates
New trials, FDA decisions, and legal changes for MDMA and SSRIs — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.